Key result
Fimasartan was associated with a numerically lower but non-significant 3-year risk of MACE compared to CCBs in adults with hypertension (HR 0.895; 95% CI 0.796-1.006; p=0.0628).
Why the study?
Real-world outcome data comparing fimasartan specifically with calcium channel blockers in hypertension are limited.
Does fimasartan reduce major adverse cardiovascular events compared to calcium channel blockers in adults with hypertension and no prior cardiovascular disease?
Cohort
Yes
Does fimasartan reduce major adverse cardiovascular events compared to calcium channel blockers in adults with hypertension and no prior cardiovascular disease?
Hazard Ratio: 0.895 (95% CI 0.796–1.006)
p-value: p=0.0628
Real-world data suggests fimasartan may offer comparable or potentially improved cardiovascular event profiles relative to CCBs in uncomplicated hypertension, though primary treatment-naïve analysis results did not reach statistical significance.
Fimasartan may suit treatment-naïve hypertension without prior CVD; leaves open comparative effectiveness versus CCBs pending randomized data.
Background: Fimasartan is an angiotensin II receptor blocker (ARB) that was developed in Korea. Although ARBs and calcium channel blockers (CCBs) are both recommended first-line antihypertensive drug classes, real-world outcome data comparing fimasartan specifically with CCBs remain limited. Methods: We analyzed Korean National Health Insurance Service data for adults aged ≥20 years with hypertension and no prior cardiovascular disease. The primary inferential analysis was treatment-naïve new users of fimasartan or CCB monotherapy using a 30-day landmark design, with outcome follow-up beginning on day 31. The primary endpoint was 3-year major adverse cardiovascular events (MACEs), defined as all-cause death, cardiac death, nonfatal myocardial infarction, or nonfatal stroke. Multivariable Cox models were used for the primary analysis, while broader overall-cohort and propensity-score-matched analyses were considered secondary. Results: In the primary treatment-naïve new-user analysis, fimasartan was associated with a numerically lower MACE risk than CCBs, although the 95% confidence interval included the null value (adjusted HR 0.895, 95% CI 0.796–1.006; p = 0.0628). In secondary analyses of the broader overall cohort, fimasartan was associated with a lower adjusted MACE risk (HR 0.851, 95% CI 0.815–0.890), and the association remained evident after propensity-score matching (HR 0.675, 95% CI 0.653–0.699). Exploratory comparisons showed nearly identical crude MACE rates for fimasartan+CCB and fimasartan+thiazide regimens (3.46% vs. 3.47%). Conclusions: In this nationwide observational cohort, the primary treatment-naïve new-user analysis showed a numerically lower 3-year MACE risk with fimasartan than with CCBs, although the confidence interval included the null value. Stronger associations observed in secondary analyses of the broader cohort should be interpreted cautiously because residual confounding and selection bias cannot be excluded.
No takes yet. Share an insight, caveat, or question.
Ahn et al. (2026) conducted a cohort in Hypertension. Fimasartan vs. Calcium Channel Blockers (CCBs) was evaluated on 3-year major adverse cardiovascular events (MACEs), defined as all-cause death, cardiac death, nonfatal myocardial infarction, or nonfatal stroke (HR 0.895, 95% CI 0.796-1.006, p=0.0628). Fimasartan was associated with a numerically lower but non-significant 3-year risk of MACE compared to CCBs in adults with hypertension (HR 0.895; 95% CI 0.796-1.006; p=0.0628).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: